GSK plc is a healthcare company that researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease. It operates through Commercial Operations and Total R&D segments. Its portfolio includes specialty medicines for oncology, respiratory/immunology, inflammation, and HIV, as well as vaccines for shingles, meningitis, RSV, influenza, hepatitis, and other diseases, and general medicines for asthma, COPD, and bacterial infections. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. Founded in 1715, it is headquartered in London, United Kingdom.
GSK's pipeline and dealmaking drive gains, but tariff risk lingers
▲
FDA approval of Utebzi GSK and Spero won FDA approval for Utebzi, the first oral carbapenem for complicated UTIs. This opens a new market and strengthens GSK's anti-infectives portfolio, with launch expected by end-2026.
This is a concrete regulatory win that directly boosts GSK's revenue prospects.
▲
M&A surge and GSK's Nuvalent deal Biopharma M&A hit a six-year high with $65 billion in Q1 deals, and GSK is acquiring Nuvalent for $10.6 billion. This shows GSK is actively filling pipeline gaps, which investors view as a growth signal.
The Nuvalent acquisition is a major strategic move that addresses pipeline concerns and reflects industry confidence.
▲
Physician interest in Benlysta for CTD-ILD A survey shows rheumatologists are highly interested in GSK's Benlysta for CTD-ILD, a condition with few effective treatments. This hints at potential expanded use and future sales growth.
It points to a possible new indication for an existing GSK drug, which could add revenue.
▼
US tariff and policy concerns Industry confidence is high, but 69% of executives cite US tariffs and government actions as the biggest worry, rising to 78% among Europeans. For GSK, a UK-based company, this could mean higher costs or barriers in its largest market.
It provides a real counterweight to the positive news, highlighting a risk that could pressure the stock.
Latest
▲2▼1
GSK pipeline wins and buybacks offset HIV patent cliff and flu competition
▲
Specialty Medicines growth and pipeline expansion GSK's Specialty Medicines sales rose 14% in H1 2026, now over 40% of total sales, with double-digit growth in HIV, respiratory, immunology and oncology. The company plans more than 20 late-stage studies in 2026, more than double its original target, supporting long-term revenue growth and lifting the shares.
This shows the core growth engine that is driving GSK's earnings and share price higher.
▼
HIV patent cliff looms GSK faces loss of exclusivity for dolutegravir, the backbone of its HIV medicines, with patents expiring in major markets around 2028-2029. Those products generated £2.74 billion in H1 2026 sales, so the eventual loss of protection threatens a significant revenue stream and weighs on the share price.
This is a major medium-term risk that could pressure future earnings and investor sentiment.
▲
Oncology pipeline boosted by lung cancer data and Chimagen deal GSK rose 4.7% after positive trial results for two lung cancer treatments. It also acquired full global rights to Chimagen's trispecific T-cell engager for multiple myeloma for up to $750 million, expanding its oncology pipeline and reinforcing growth prospects.
These are concrete pipeline advances that directly lifted the stock and add new oncology assets.
◆
Vaccine restructuring and mRNA flu advance GSK will close its Dresden vaccine plant by 2027, cutting 641 jobs, to consolidate flu vaccine production in Canada amid falling demand for egg-based vaccines. At the same time, it advanced its mRNA flu vaccine to Phase III after strong mid-stage results, aiming to defend its flu franchise against new competitors like Moderna.
This shows GSK cutting costs and investing in next-generation vaccines to offset competitive threats.
Q3 2026
▲2▼2
GSK's new drug wins offset pipeline setbacks and legal risks
▲
FDA approval of Jiditro and other regulatory wins GSK won FDA approval for Jiditro, its first lung cancer drug, plus regulatory nods for Jemperli and Hibsago. These expand GSK's oncology and specialty portfolios, offering new sales streams.
New drug approvals are major positive catalysts for future revenue.
▲
Strong Q2 results and cost-savings plan GSK reported 5% sales growth in Q2, raised full-year guidance, and announced a £1.9bn cost-savings plan. Specialty Medicines grew 14%, showing core business strength and efficiency gains.
Financial performance and cost cuts directly boost investor confidence.
▼
Pipeline setback and legal threat GSK dropped camlipixant, a potential £2.5bn product, and faces AnaptysBio's lawsuit over Jemperli rights. These create uncertainty about future revenue and legal costs.
Pipeline failures and litigation are key negative drivers for the stock.
▼
Competition and patent cliff concerns Moderna's mRNA flu vaccine challenges GSK's flu franchise, and the dolutegravir HIV patent cliff looms around 2028–29, threatening £2.74bn in H1 2026 sales. Vaccine restructuring cuts 641 Dresden jobs.
Competitive threats and patent expirations weigh on long-term growth outlook.
News & notes movingGSK.LSE
United States
Aging Population▲
Trump Administration Picks 10 Drugmakers for New 340B Rebate Pilot
The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.
Aging Population › Chronic-Disease Pharma Franchises Regulation
4503.JP · Regulation · Positive Astellas is one of the selected manufacturers participating in the 340B rebate pilot program.
ABBV · Regulation · Positive AbbVie is one of 10 selected manufacturers in the new 340B rebate pilot, allowing it to pay rebates after purchase rather than upfront discounts.
AMGN · Regulation · Positive Amgen is selected for the 340B Rebate Model Pilot, shifting it to a post-purchase rebate model for discounted drugs.
AZN.LSE · Regulation · Positive AstraZeneca is selected for the 340B rebate pilot, letting it verify and pay rebates rather than give upfront discounts.
BMY · Regulation · Positive Bristol Myers is among the 10 drugmakers chosen for the administration's 340B rebate pilot taking effect January 1.
GSK.LSE · Regulation · Positive GSK is named among the 10 drugmakers in the new 340B rebate model pilot taking effect January 1.
CDC Acknowledges One Pennsylvania Measles Death After Weeks of Resistance
The CDC has acknowledged one of the four measles-related deaths reported by Pennsylvania, ending weeks of resistance by the agency. The CDC's "Measles Cases and Outbreaks" page lists 3,471 cases nationwide as of Sept. 18, compared with 2,289 in all of 2025. Of the 3,471 cases, 9 percent, or 301 individuals, have resulted in hospitalizations, and 95 percent of all cases were in people not vaccinated with the MMR shot, which Merck and GSK market in the U.S. Pennsylvania is the hardest-hit state, with 792 cases as of Sept. 21. Pennsylvania Secretary of Health Debra Bogen recently asked the CDC for rapid-response assistance known as Epi-Aid, but only if the agency recognizes the state's four measles-associated deaths.
GSK Targets Over £40 Billion in Sales as Oncology and £1.9 Billion Savings Plan Take Shape
GSK is targeting more than £40 billion in sales, above the £36.4 billion consensus estimate, with oncology assets driving much of the potential upside, Chief Financial Officer Julie Brown said in a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day. Brown said the largest difference between GSK's outlook and consensus lies in oncology, citing the antibody-drug conjugate portfolio including assets referred to as MORES and RISRES, as well as BLENREP and Jemperli. The company's simplification program is expected to generate £1.9 billion in savings, with most of the savings intended to fund pipeline investment and support margins through upcoming patent expirations for dolutegravir-based HIV medicines; GSK expects margins to be stable to improving from 2028 through 2030. GSK's strategic portfolio review identified seven major assets across roughly 18 indications for accelerated development, and specialty products, which accounted for just over 40% of the business compared with roughly one-third when Brown joined in early 2023, are expected to exceed 50% by 2031. Key growth opportunities include the launches of Excentia, BLENREP, bepirovirsen and Nuvalent-derived medicines, while TRELEGY pricing pressure under the Inflation Reduction Act and tougher SHINGRIX comparisons are expected to weigh on 2027 performance.
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Demand
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
GSK.LSE · Capital · Positive GSK targets over £40 billion in sales above consensus and a £1.9 billion savings program, with oncology driving upside.
GSK.LSE · Pricing · Negative TRELEGY pricing pressure under the Inflation Reduction Act and tougher SHINGRIX comparisons are expected to weigh on 2027 performance.
NUVL · Demand · Positive GSK lists Nuvalent-derived medicines among key growth opportunities, implying demand for Nuvalent's assets.
European UnionUnited KingdomUnited StatesChinaDenmarkFranceSwitzerland
Biotech & Genomic Medicine▼impact 4
AstraZeneca and GSK Warn Europe's Drug Industry Is 'At Risk'
AstraZeneca and GSK have joined European rivals Novo Nordisk, Sanofi, Roche and Novartis in an open letter warning that Europe's pharmaceutical industry is "losing ground to global competition" and faces a "slow agony" of decline without urgent action. The executives, including AstraZeneca chairman Michel Demaré and GSK chairman Sir Jonathan Symonds, said Europe's share of global pharmaceutical research and development has fallen from 43pc in 1990 to 31pc today, while China has overtaken Europe in clinical trials, pharmaceutical patents and new medicine development. The letter warned that up to 40pc of newly approved therapies never reach European patients, and that patients wait nearly 600 days for drugs that do arrive, putting Europe's €220bn trade surplus in drugs at risk. Closing the gap in clinical trials would unlock up to €53bn alone and create 82,000 jobs, the letter added. The intervention comes amid a broader dispute over European incentives for life-sciences investment, after US President Donald Trump accused Europe of "freeloading" on the American drug industry and threatened tariffs, prompting cuts to NHS rebate rates that added billions of pounds in costs to the taxpayer; AstraZeneca has separately announced plans to invest $50bn in the US and completed a direct listing there earlier this year.
Biotech & Genomic Medicine › Oncology Therapeutics ▼Regulation
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity ▼Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▼Regulation
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▼Regulation
AZN.LSE · Regulation · Negative AstraZeneca's chairman warns Europe's pharma R&D is losing ground and up to 40% of approved therapies never reach European patients, citing regulatory/incentive failures.
GSK.LSE · Regulation · Negative GSK's chairman joins the letter warning Europe's drug industry faces decline from weak incentives and slow patient access to new medicines.
NVO · Regulation · Neutral Named as a European rival joining the open letter warning on EU pharma competitiveness and incentives; no company-specific development.
AstraZeneca's Tozorakimab Cuts COPD Flare-Ups by 30% in Late-Stage Trials
AstraZeneca PLC released full results from two successful late-stage trials of tozorakimab, an experimental chronic obstructive pulmonary disease drug that reduced moderate and severe flare-ups by roughly 30% across a broad patient population. The two trials showed reductions in moderate-to-severe COPD exacerbations of 29% to 34%, with the highest-eosinophil subgroup seeing a 43% reduction, and benefits appearing regardless of eosinophil levels, smoking status, or disease severity. The biologic, which blocks the inflammatory protein IL-33, is under priority review at the FDA with a decision expected in the first quarter of 2027, and AstraZeneca forecasts more than $5 billion in peak annual sales, an estimate CEO Pascal Soriot said the drug's commercial potential could exceed. AstraZeneca believes tozorakimab could reach a broader group of COPD patients than existing biologics such as Regeneron and Sanofi's Dupixent and GSK's Nucala, which only target those with high eosinophil counts. The company's oncology and respiratory portfolio made $14.1 billion in first-half 2026 revenue, up 15% year over year, as AstraZeneca targets $80 billion in annual revenue by 2030, though the drug still needs FDA approval and faces patent-expiry pressure on established products including Farxiga and Brilinta.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Demand
AZN.LSE · Technology · Positive Late-stage tozorakimab trials cut moderate-to-severe COPD flare-ups by ~30% across a broad population, with FDA priority review and >$5B peak sales forecast
GSK.LSE · Competition · Negative AstraZeneca claims tozorakimab could reach a broader COPD group than GSK's Nucala, which only targets high-eosinophil patients
REGN · Competition · Negative AstraZeneca says tozorakimab could reach a broader COPD population than Regeneron/Sanofi's Dupixent, which only targets high-eosinophil patients
SAN.PA · Competition · Negative AstraZeneca says tozorakimab could reach a broader COPD population than Sanofi/Regeneron's Dupixent, which only targets high-eosinophil patients
AstraZeneca's $15bn China bet tests West's fragile drug alliance
AstraZeneca has pledged to invest $15bn in China, deepening Western pharmaceutical ties with a country that has become a bona fide drug superpower even as Washington moves to sever them. The company's chief executive, Sir Pascal Soriot, announced the investment during Sir Keir Starmer's Beijing visit, building on existing manufacturing and research sites in Beijing, Shanghai, Wuxi, Taizhou and Qingdao; China is now AstraZeneca's second-largest market, accounting for roughly 12pc of global turnover, with around 17,000 employees and four advanced manufacturing sites. GSK has struck a series of partnerships with Chinese labs, including a $1.3bn pact with Hutchmed for the bulk of licensing rights to what it called first-in-class cancer treatments, and an alliance with Hengrui Pharma worth up to $12bn. Industry-wide licensing deals totalled $138bn last year, a nearly tenfold jump since 2021, according to PharmCube. The US Biosecure Act, signed into law in December, bars companies reliant on federal contracts from working with Chinese biotech firms tied to the military, and the proposed Biotech Investment National Security Act would subject licensing deals involving Chinese companies to national security reviews. China had 1,255 drugs at the research stage by 2024, a nearly eight-fold jump in less than a decade, against 1,441 in America and 400 in Europe.
Biotech & Genomic Medicine › CDMO / Contract Manufacturing ▲Capital
Biotech & Genomic Medicine › Oncology Therapeutics Competition
Biotech & Genomic Medicine › Metabolic, Diabetes & Obesity Competition
AZN.LSE · Capital · Positive AstraZeneca pledged a $15bn investment in China, expanding its manufacturing and research footprint.
GSK.LSE · Demand · Positive GSK struck partnerships with Chinese labs including a $1.3bn Hutchmed pact and a $12bn Hengrui alliance.
0013.HK · Demand · Positive GSK struck a $1.3bn pact with Hutchmed for licensing rights to first-in-class cancer treatments, a concrete deal for Hutchmed.
600276.CG · Demand · Positive GSK formed an alliance with Hengrui Pharma worth up to $12bn, a major licensing deal for Hengrui.
GSK Buys Chimagen Trispecific T Cell-Engager for Multiple Myeloma
GSK agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, a drug asset the parties describe as a potential best in class trispecific T cell therapy. The deal expands GSK's blood cancer research portfolio and complements recent moves such as the Nuvalent acquisition that brought in Jideytro. Separately, GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The key test will be whether GSK hits its stated timeline to move the trispecific T cell-engager into phase I trials in 2027, while advancing Jideytro's first line FDA submission planned for 2026. GSK is a £74.8b pharmaceuticals group that develops vaccines, specialty treatments and general medicines across major markets.
GSK to Close Dresden Vaccine Plant, Cutting 641 Jobs by 2027
GSK plc plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The company reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to consolidate production in Canada, which it says can meet anticipated demand more sustainably and competitively, as falling demand for traditional egg-based flu vaccines has left GSK with more manufacturing capacity than it needs. The closure comes as GSK advances an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard-dose vaccines in younger adults and high-dose vaccines in older adults. GSK's vaccine business remains a significant earnings contributor, with second-quarter 2026 vaccine sales rising 8% to £2.3 billion, meningitis vaccines up 21%, Arexvy sales increasing by more than 100%, and Shingrix generating £0.9 billion. The company faces execution risk, as the mRNA flu candidate has only reached Phase III and opposition from the German union and works council could make the closure process more complicated or expensive.
Biotech & Genomic Medicine › Vaccines (Recombinant & Traditional) ▼Supply
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
GSK.LSE · Supply · Negative GSK is closing its Dresden vaccine plant and cutting 641 jobs to consolidate flu vaccine production in Canada amid excess capacity from falling egg-based flu vaccine demand.
GSK.LSE · Technology · Positive GSK is advancing an mRNA-based seasonal flu vaccine into Phase III after Phase II results showed stronger immune responses than standard and high-dose vaccines.
European stocks mixed as German 10-year bond yield hits highest level in over 17 years
In European markets on the 14th, the German 10-year bond yield rose by more than 4 basis points to 3.5544%, its highest level in over 17 years. Inflation concerns driven by higher crude oil prices and rising bond yields weighed on the market, with the STOXX Europe 600 falling 0.49% to 635.99, Germany's DAX down 0.50% to 25,440.81, and France's CAC 40 down 0.76% to 8,117.78. Meanwhile, London's FTSE 100 extended its gains, rising 0.44% to 10,697.57, as pharmaceutical and consumer staples stocks were bought. GSK rose 4.7% after announcing positive trial results for two lung cancer treatments, while data analytics firm GlobalData fell 18.7% after its full-year revenue forecast fell short of market expectations. Expectations are growing in the market that major central banks will raise interest rates within the year, with the ECB expected to implement at least one more rate hike this year, and markets fully pricing in two 25 basis point hikes by February 2027.
DE-10Y.GB · Monetary · Positive German 10-year bond yield rose over 4bp to 3.5544%, its highest in over 17 years, on inflation concerns and expectations of central bank rate hikes.
GSK.LSE · Technology · Positive GSK rose 4.7% after announcing positive trial results for two lung cancer treatments.
High-Grade Bond Issuance Hits $57 Billion in Two Days After Labor Day
High-grade bond issuance surged to $57 billion across 30 offerings on Tuesday and Wednesday alone in the holiday-shortened week after Labor Day, putting September on pace for a fourth straight monthly record. June, July and August totals of $184 billion, $137 billion and $151 billion were the highest ever for those months, according to LCD, and syndicate desks are now suggesting September supply of well over $200 billion, which would supplant last September's unprecedented $189 billion output. That year-ago record included the first major shot in the ongoing AI debt barrage, an $18 billion blockbuster print for Oracle, whose 5.95% notes due 2055 now yield roughly 7.875% on dollar prices south of 79% of par, with investors demanding spreads of T+245 versus the T+125 pricing level a year earlier. This week's biggest deals are GlaxoSmithKline's $6.5 billion offering backing its Nuvalent acquisition and a $6 billion print for UBS, though the week's average deal size of $1.9 billion trails this year's record-setting average through August by about $220 million. Roughly 20% of last month's proceeds, or $31 billion across 10 offerings, were earmarked for M&A funding, the highest share since May, while August data center and AI financing cooled from the prior two months but still included Alphabet's $25 billion package of 10 tranches and Blackstone-backed QTS Central Issuer's debut $3.9 billion offering of 6.625% five-year senior secured data center bonds.
GSK Advances mRNA Flu Vaccine to Late-Stage After Strong Mid-Stage Results
GSK plc is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate generated stronger immune responses than currently approved standard-dose flu vaccines in younger adults and approved high-dose vaccines in older adults, according to GSK. Its design also targets two important surface proteins on the influenza virus, haemagglutinin and neuraminidase, rather than focusing on one. GSK said the late-stage study will be the first for an mRNA seasonal flu vaccine designed to target both proteins, and the company believes this approach could improve protection and reduce transmission. GSK intends to begin the late-stage trial in September 2026, part of a wider effort to accelerate its pipeline that, following a portfolio review by CEO Luke Miels, includes plans to initiate more than 20 late-stage studies by the end of 2026 as the company prepares for approaching patent expirations.
GSK Specialty Medicines Sales Rise 14% as HIV Patent Cliff Looms
GSK's Specialty Medicines unit, which now accounts for more than 40% of the company's sales and is expected to exceed 50% of total revenues by 2031, posted 14% sales growth at CER in the first half of 2026 on double-digit gains across HIV, Respiratory, Immunology & Inflammation and Oncology. New long-acting HIV injectables Cabenuva and Apretude account for around 25-30% of total HIV sales, while newer oncology drugs Jemperli and Ojjaara and recent launches including Blenrep, Exdensur and Penmenvy broaden the growth base, and GSK expects low double-digit percentage sales growth in the segment for 2026 at CER. The company now expects more than 20 phase III starts in 2026, more than twice the 10 originally contemplated, and has 19 assets in late-stage development or under regulatory review, with FDA decisions on bepirovirsen for chronic hepatitis B and neladalkib for non-small cell lung cancer expected later this year. GSK faces the loss of exclusivity for dolutegravir, the backbone of HIV medicines including Tivicay, Triumeq and Dovato, with patents expected to begin expiring in major markets around 2028-2029; dolutegravir-based products generated £2.74 billion in sales in the first half of 2026. GSK expects to launch twice-yearly long-acting injectables for treatment and PrEP between 2028 and 2030, and competes in Specialty Medicines with AstraZeneca, Merck, Sanofi, Gilead, Pfizer, J&J and Novartis, among others.
Biotech & Genomic Medicine › Antiviral & Infectious-Disease Therapeutics ▲Demand
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics ▲Demand
GSK.LSE · Demand · Positive Specialty Medicines sales rose 14% at CER in H1 2026 on double-digit gains across HIV, Respiratory, Immunology & Inflammation and Oncology, with GSK guiding to low double-digit growth for 2026.
GSK.LSE · Regulation · Negative GSK faces loss of exclusivity for dolutegravir, the backbone of HIV medicines including Tivicay, Triumeq and Dovato, with patents expected to begin expiring in major markets around 2028-2029.
HUTCHMED Signs $1.3B GSK Deal for KRAS-EGFR Cancer Therapy
HUTCHMED has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, in a deal worth up to approximately $1.3 billion. The agreement includes a $110 million upfront payment and potential tiered royalties, with HUTCHMED leading global Phase I development before GSK assumes responsibility outside China. HMPL-A830 is designed to target EGFR-overexpressing tumor cells and deliver a KRAS payload, potentially addressing resistance to standalone KRAS inhibitors in colorectal, pancreatic, and lung cancers. HUTCHMED also granted GSK a right of first negotiation on another early-stage candidate from its ATTC platform. The company expects to present detailed data from two positive Phase III trials with AstraZeneca at a future conference, and anticipates milestone and royalty income from commercialized indications, including tiered royalties of 9% to 13% on global sales for the SAFFRON trial and 30% royalties from AstraZeneca for specified indications in China.
Osteosarcoma Market to Reach USD 60 Million by 2036 with 8 Emerging Therapies
DelveInsight forecasts that the osteosarcoma market across the seven major markets—the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan—will grow at a CAGR of 9% from approximately USD 60 million in 2025 through 2036, driven by eight emerging therapies including OST-HER2, DANYELZA, Vactosertib, and Risvutatug rezetecan. OST-HER2, developed by OS Therapies, is a HER2-targeted immunotherapy that has received FDA Fast Track and Orphan Drug Designations, with a planned Biologics License Application under the Accelerated Approval pathway in the second half of 2026, and is projected to generate about USD 37 million across the 7MM by 2036. Other notable candidates include SERB Pharmaceutical's DANYELZA, an anti-GD2 antibody with a niche profile, and GSK's Risvutatug rezetecan, an ADC targeting B7-H3 that received Breakthrough Therapy Designation in 2025. The pipeline remains concentrated in early-stage trials, with limited late-stage data posing challenges for regulatory approval, but increasing research in targeted and immunotherapies is expanding the landscape.
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Competition
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
OSTX · Technology · Positive OST-HER2, OS Therapies' HER2-targeted immunotherapy, is a key emerging osteosarcoma therapy with FDA Fast Track/Orphan designations and a planned BLA in 2H 2026, projected ~USD 37M by 2036
GSK.LSE · Technology · Positive GSK's Risvutatug rezetecan, a B7-H3-targeting ADC, received Breakthrough Therapy Designation in 2025 and is among the emerging osteosarcoma therapies
SERB Pharmaceutical · Technology · Positive SERB Pharmaceutical's DANYELZA, an anti-GD2 antibody, is listed among the emerging osteosarcoma therapies with a niche profile
GSK plc announced it will advance its mRNA-based seasonal influenza vaccine candidate into Phase III development, following positive Phase II results showing higher immune responses compared with standard-dose and high-dose flu vaccines in younger and older adults, respectively. The company plans to start the Phase III efficacy study in September 2026, which will be the first study of an mRNA flu vaccine designed to target both haemagglutinin and neuraminidase, potentially improving protection against illness and transmission. The FDA has granted Fast Track designation for the candidate. Year to date, GSK stock has risen 6.1%, while rival Moderna's shares jumped nearly 10% on the news, as investors viewed it as platform validation rather than a threat to its recently approved mRNA flu vaccine, mFlusiva.
GSK Wins First Global Approval for Chronic Hepatitis B Cure
GSK has received the world's first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B virus infection in Japan. The approval follows Phase III trial data showing significant functional cure rates in patients. This decision marks a key milestone for GSK's pipeline and could influence global treatment standards. GSK, a major pharmaceuticals company with a market cap of about £75.0b, focuses on vaccines and specialty medicines, and this approval fits within its infectious disease portfolio. The company still needs to demonstrate how bepirovirsen's access, pricing, and follow-on indications compare with peers like Pfizer and Merck, and whether this asset can offset risks from patent expiries and legal cash outflows.
GSK mRNA Flu Shot Shows Superior Immune Response, Phase 3 Trial Set for September
GSK plc plans to launch a Phase 3 clinical trial in September for its experimental mRNA seasonal influenza vaccine after mid-stage data showed superior immune responses compared to licensed vaccines. The candidate, FLUm3HA.b-3NA, targets both haemagglutinin and neuraminidase surface antigens, a first for an mRNA flu vaccine. In the Flu-028 trial involving 971 adults, the vaccine generated higher immune responses against every tested strain than standard and high-dose inactivated vaccines, with acceptable safety. The U.S. Food and Drug Administration granted Fast Track designation in July 2026. GSK shares rose 0.46% to $50.48 in premarket trading.
Moderna Gets FDA Approvals for Updated COVID and First mRNA Flu Shots
Moderna received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant, as well as mFlusiva, its first mRNA-based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA-authorized mRNA flu shot for older adults. The company, a US-based biotechnology firm developing messenger RNA medicines, sees these approvals as reinforcing its regulatory momentum and diversifying its respiratory offerings against competitors like Pfizer and Novavax in COVID and Sanofi and GSK in flu. However, analysts note that respiratory shots still depend on annual uptake, pricing, and pharmacy stocking, so the key question is how far these launches reduce reliance on a narrow set of seasonal products.
GSK's Jemperli gets FDA priority review for rectal cancer
GSK said the FDA has accepted its supplemental Biologics License Application for Jemperli, also known as dostarlimab, for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The FDA has set a PDUFA action date of February 2027. The application is also eligible for expedited review under the National Priority Voucher program, which could lead to an earlier FDA decision. The application is based on positive data from the registrational phase II, single-arm AZUR-1 trial, which met its primary objective by demonstrating a meaningful and sustained clinical complete response rate for 12 months with no detectable signs of cancer for at least one year.
Trump executive order unlikely to hit vaccine makers, analysts say
Seeking Alpha analysts say President Donald Trump's executive order changing childhood vaccine recommendations is unlikely to materially hurt vaccine makers. Stephen Ayers called the order directionally negative for pediatric vaccine-heavy names but expects it to be challenged and go unimplemented, noting Merck's M-M-R II, ProQuad, and Varivax generated $592 million in Q2 2026. ALLKA Research said Merck and GSK are key players, with GSK's Priorix, Priorix Tetra, and Varilrix generating only $97 million in sales, and that any policy change would likely face litigation from groups such as the American Academy of Pediatrics. Gen Alpha expects little to no impact because the executive order is not law and is unlikely to change public perception.
GSK Reports Q2 Results and Accelerates Pipeline Plans
GSK reported second-quarter financial results on July 28, with total turnover rising 5% at constant exchange rates to £8.4 billion, while core operating profit climbed 7% to £2.80 billion and core EPS rose 9% to 50.5p. Total operating profit dropped 75% to £481 million after a £1.3 billion non-cash impairment charge tied to discontinuing camlipixant following Phase III trial results. Management announced it now expects more than 20 Phase III trial starts in 2026, up from a prior projection of 10, and launched a three-year 'Accelerate Growth' restructuring program aimed at generating £1.9 billion in annual cost savings by 2029 at a total cost of £2.4 billion. ViiV Healthcare, GSK's majority-owned HIV business, presented positive Phase IIIb VOGUE study data supporting its long-acting HIV regimen portfolio.
Experts warn splitting MMR vaccine could take a decade
President Donald Trump's executive order aimed at splitting the combined measles, mumps and rubella vaccine faces a major hurdle because none of the individual disease shots are currently licensed in the U.S. Only Merck and GSK are licensed to make combined MMR shots for U.S. patients, and Merck stopped manufacturing individual vaccines for these diseases nearly two decades ago. Merck said even under current expedited review pathways it could take years, potentially as many as 10, to meet safety and efficacy requirements for FDA approval and begin manufacturing and commercialization of single-disease shots. Andrew Racine, president of the American Academy of Pediatrics, said each constituent would have to be manufactured and tested, and that drugmakers probably could not do that for another 10 years. The American College of Physicians warned the order could increase costs to patients and families and place a greater burden on families needing multiple appointments.
Spero Therapeutics Reports Q2 2026 Loss, FDA Approval of Utebzi
Spero Therapeutics reported a net loss of $9.6 million for the second quarter of 2026, compared to a net loss of $1.7 million in the same period last year, while highlighting the FDA approval of its antibiotic Utebzi. The company recorded no revenue in the quarter, down from $14.2 million a year earlier, as prior collaboration revenue from Pfizer and GSK was fully realized. Research and development expenses fell to $3.4 million from $10.7 million due to reduced clinical activity, while general and administrative expenses rose to $6.5 million from $5.9 million. Spero also announced it closed a $105 million non-dilutive, non-recourse royalty financing with Healthcare Royalty, extending its cash runway into the second half of 2029. The company said the FDA approved Utebzi on June 17, 2026, for complicated urinary tract infections, making it the first oral carbapenem approved in the US, with GSK holding exclusive commercialization rights worldwide excluding certain Asian territories.
GSK Prelet Drives UK Lab Space Demand to Record High
GSK's landmark life sciences prelet has driven UK laboratory space demand to a new record, according to data from CoStar. Rolling four-quarter take-up exceeded 1.2 million square feet in the third quarter of 2026, with two months still remaining, following the 300,000-square-foot prelet at Cambridge Biomedical Campus. Cambridge activity has rebounded in 2026, with year-to-date leasing volumes above 180,000 square feet, nearly double Oxford's total, and the GSK deal brings volumes in the first seven months to almost 500,000 square feet, matching the previous record year in 2015. However, UK laboratory vacancies reached a record 14.3 percent in the second quarter, more than doubling in two years as Golden Triangle levels exceeded 25 percent, following 1.8 million square feet of new lab space delivered over the past two years. Geopolitical risks, economic uncertainty, and rising construction costs are expected to slow development, with less than 130,000 square feet starting on site so far in 2026, one of the lowest levels on record, reducing the UK construction pipeline to around 3 million square feet, down about 13 percent since the start of the year.
GSK to open Cambridge R&D hub and partner with Relation Therapeutics
GSK plans to establish a new global R&D centre on the Cambridge Biomedical Campus in the UK, expected to accommodate more than 1,000 scientists. The company has also agreed a research collaboration with Relation Therapeutics that uses advanced cellular biology models and large-scale data generation. The move places GSK at the heart of one of Europe's leading life sciences hubs and signals a stronger focus on data-driven and AI-supported drug discovery.
Biotech & Genomic Medicine › AI Drug Discovery ▲Technology
GSK.LSE · Technology · Positive GSK opens new R&D hub and partners with Relation Therapeutics to advance data-driven drug discovery.
Relation Therapeutics · Technology · Positive Relation Therapeutics gains a research collaboration with GSK, leveraging its cellular biology models and data generation.
Relation and GSK expand collaboration on AI-driven drug discovery
Relation announced an expanded strategic research collaboration with GSK to generate large-scale human cellular perturbation data and deploy them into models, including Relation's cellular biology foundation model MORGAN, to deepen understanding of disease biology and support the discovery of potential new therapeutic targets. Under the agreement, Relation may receive up to $110 million in upfront and success-based milestone payments. The collaboration will create high-quality perturbation datasets capturing how human cells respond to genetic and pharmacological interventions, using integrated automation to generate time-resolved data with multi-omics readouts at significant scale and consistency. The resulting data asset will be used to train foundation models and investigate biological pathways, supporting future research aimed at identifying novel therapeutic opportunities. The effort reflects a shared commitment to advancing drug discovery through innovative human biology, large-scale data generation, and foundation model development.
Biotech & Genomic Medicine › AI Drug Discovery ▲Technology
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
Artificial Intelligence › AI Applications & Copilots ▲Technology
Relation Therapeutics · Capital · Positive Relation may receive up to $110 million in upfront and milestone payments from GSK under the expanded collaboration.
GSK.LSE · Technology · Positive GSK expands AI-driven drug discovery collaboration with Relation, gaining access to large-scale perturbation data and foundation models to identify new therapeutic targets.
GSK Reports 5% Sales Growth in Q2 2026, Updates Guidance and Pipeline Plans
GSK reported second-quarter 2026 sales rose 5% to more than GBP8.4 billion, with core operating profit up 7% and core earnings per share up 9%. Specialty Medicines revenue grew 14% and Vaccines grew 8%, while General Medicines declined 9%. The company updated its full-year 2026 sales and operating profit guidance towards the upper half of the range, but lowered its EPS outlook to the lower half due to additional interest costs of around GBP160 million from the Nuvalent acquisition. GSK also announced a new 'Accelerate Growth' program targeting GBP1.9 billion in annual cost savings by 2029, and plans to start over 20 Phase III trials in 2026, more than double initial expectations.
Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?
Moderna is set to report second-quarter 2026 earnings on July 31 before the opening bell, with the Zacks Consensus Estimate pegging sales at $126.7 million and a loss of $1.97 per share. The revenue figure suggests a decline from the year-ago levels, but the bottom line is expected to improve. Over the past 30 days, the Zacks Consensus Estimate for 2026 loss per share has widened from $8.26 to $8.64, while the 2027 loss estimate has risen from $4.29 to $4.33. The biotech has beaten earnings estimates in each of the trailing four quarters, delivering an average surprise of 46.21%, including a 60.93% beat in the last reported quarter. However, the Zacks model does not predict a beat this time, as Moderna has an Earnings ESP of -2.41% and a Zacks Rank of 3. Key factors shaping the upcoming results include product sales from two COVID-19 vaccines, Spikevax and mNexspike, and the RSV vaccine mResvia, with the majority of sales expected from COVID-19 vaccines and minimal sales from mResvia due to stiff competition from GSK's Arexvy and Pfizer's Abrysvo. Investors will also seek updates on the commercialization plans for mCombriax, the first combination vaccine against COVID-19 and influenza, which secured EU approval in April, as well as the timeline for FDA resubmission after the initial filing was voluntarily withdrawn last year. Additionally, the FDA decision on Moderna's standalone flu shot, mRNA-1010, is expected by next week, with optimism building after an FDA advisory committee unanimously backed approval. Another key pipeline candidate is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck, which is being evaluated in three pivotal phase III studies in melanoma and non-small cell lung cancer, along with mid-stage studies for other cancer indications. Year to date, Moderna's shares have surged 89%, significantly outperforming the industry's 2% growth, the sector, and the S&P 500, though the stock trades at a premium valuation of 9.91 times trailing 12-month sales compared to the industry's 2.35. Moderna held approximately $8.1 billion in cash and cash equivalents as of March 31, 2026, which, combined with cost-efficiency initiatives, should support its research, development, and commercialization efforts. While the premium valuation and downward estimate revisions warrant caution, existing investors are advised to maintain their positions given the approaching FDA decision on mRNA-1010, the recent EU approval of mCombriax, and a deep pipeline spanning oncology and other therapeutic areas.
Biotech & Genomic Medicine › mRNA Platforms ▼Demand
MRNA · Capital · Neutral Earnings preview with mixed signals: expected sales decline but bottom-line improvement, past beats, but current ESP negative.
GSK.LSE · Competition · Negative GSK's RSV vaccine Arexvy is mentioned as stiff competition for Moderna's mResvia.
PFE · Competition · Negative Pfizer's RSV vaccine Abrysvo is mentioned as stiff competition for Moderna's mResvia.
The FTSE 100 rose 0.8% on Tuesday, lifted by strong earnings and a drop in oil prices that offset concerns from a chip-sector sell-off in Asia. The blue-chip index closed up 89.27 points at 10,871.02, while the FTSE 250 added 0.5% and the AIM All-Share fell 0.5%. Unilever and Croda both surged 8.0% after well-received results, and GSK advanced 3.5% on better-than-expected second-quarter profit, but Barclays dropped 4.8% following what analysts called a messy set of numbers. Brent oil fell to 84.87 dollars a barrel from 89.71 dollars, and the pound was little changed at 1.3306 dollars ahead of the Federal Reserve's interest rate decision.
Gilead, GSK, and Pfizer Leaders to Headline Bioprocessing Summit 2026 Plenary on AI in Quality
Leaders from Gilead Sciences, GSK, and Pfizer will headline the opening plenary of the 18th Annual Bioprocessing Summit in Boston this August, exploring how AI and digital technologies are reshaping biopharmaceutical quality. The plenary presentation, delivered by Anthony Mire-Sluis, Senior Vice President of Global Quality at Gilead Sciences, will focus on practical strategies for integrating digital technologies and AI into quality organizations while maintaining scientific rigor and regulatory compliance. A subsequent fireside chat moderated by Susan Hynes, Global Head of Quality at GSK, will feature Mire-Sluis alongside Lynn Bottone, Senior Vice President of Quality Operations, Environment, Health & Safety at Pfizer, discussing regulatory expectations and organizational readiness. The Summit, taking place August 10-13, 2026, will bring together 1,000 scientists, engineers, and technology innovators across 12 conference tracks and more than 300 scientific presentations.
GILD · Technology · Neutral Gilead's quality leader is presenting at a conference on AI in bioprocessing, but no specific business impact is described.
GSK.LSE · Technology · Neutral GSK's quality leader is moderating a fireside chat at a conference on AI in bioprocessing, but no specific business impact is described.
PFE · Technology · Neutral Pfizer's quality leader is participating in a fireside chat at a conference on AI in bioprocessing, but no specific business impact is described.
GSK launches £1.9 billion savings drive to fund drug pipeline
GSK has launched a £1.9 billion cost-savings program to help fund late-stage studies and accelerate drug development. The three-year initiative aims to simplify the organization and reallocate capital and resources, CEO Luke Miels said in a statement. The British drugmaker also beat second-quarter profit expectations and announced a £400 million investment in the UK, including a new R&D centre. Shares rose 4.2% by 1120 GMT.
GSK.LSE · Capital · Positive GSK launched a £1.9B cost-savings program, beat Q2 profit expectations, and announced a £400M UK investment, driving shares up 4.2%.
GSK Q2 earnings expected to plunge 97% ahead of CEO strategy event
GSK is expected to report a 97.3% year-over-year decline in earnings per share when it releases second-quarter results on Tuesday before the market opens. The consensus EPS estimate stands at $1.25, while revenue is forecast to rise 37.4% to $10.98 billion. The company’s Specialty Medicines unit, which includes respiratory, immunology and inflammation, oncology, and HIV, is projected to deliver double-digit sales growth across all therapy areas, though generic competition for certain legacy products may pose a headwind. On the same day, CEO Luke Miels will host an “Accelerate Growth” event where he is expected to outline his strategy, with analysts at UBS focusing on whether he can provide a credible path to achieving the sales target of more than £40 billion by 2031 and an update on pipeline reprioritization following the acquisition of Nuvalent.
Food Allergy Market Valued at $2.7 Billion in 2025, Projected to Grow at 9.4% CAGR Through 2036
The food allergy market across the seven major markets was valued at approximately USD 2.7 billion in 2025 and is projected to expand at a robust CAGR of 9.4% through 2036, according to DelveInsight. The seven major markets comprise the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key approved therapies include peanut allergen powder (PALFORZIA), omalizumab (XOLAIR), and epinephrine nasal spray (NEFFY). The pipeline features several emerging therapies, including DBV Technologies' Viaskin Peanut Patch in Phase III, Novartis' remibrutinib in Phase II, Aravax's PVX108 in Phase II, GSK's ozureprubart in Phase II, and Aquestive Therapeutics' epinephrine sublingual film ANAPHYLM in Phase III. GSK strengthened its position through the acquisition of RAPT Therapeutics, gaining access to ozureprubart.
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
DBV.PA · Demand · Positive DBV Technologies' Viaskin Peanut Patch is in Phase III for food allergy, and the market is projected to grow at 9.4% CAGR.
AQST · Demand · Positive Aquestive's epinephrine sublingual film ANAPHYLM is in Phase III for food allergy, and the market is projected to grow at 9.4% CAGR.
GSK.LSE · Capital · Positive GSK strengthened its position through the acquisition of RAPT Therapeutics, gaining access to ozureprubart (Phase II).
NOVN.SW · Demand · Positive Novartis' remibrutinib is in Phase II for food allergy, and the market is projected to grow at 9.4% CAGR.
Aravax · Demand · Positive Aravax's PVX108 is in Phase II for food allergy, and the market is projected to grow at 9.4% CAGR.
U.S. measles cases surpass 2025 total to hit 35-year high
The U.S. has recorded 2,318 measles cases this year, exceeding the 2025 total of 2,289 and marking the highest annual count since 1991, according to the Centers for Disease Control and Prevention. As of July 23, 45 jurisdictions reported 2,302 cases, with 16 infections linked to international visitors. While no deaths have occurred this year, 151 hospitalizations were recorded, representing 7% of total cases compared with 11% in 2025. Nearly 93% of cases were in unvaccinated individuals or those with unknown vaccination status, and the CDC emphasized that the MMR vaccine, marketed by Merck and GSK, is the most effective protection. The rise comes as the U.S. risks losing its measles elimination status, achieved in 2020, with the Pan American Health Organization set to evaluate data in November after Canada lost its status last year.
GSK Could Be 10% Undervalued After Jideytro FDA Approval
GSK has received US FDA approval for Jideytro, a ROS1 selective inhibitor for previously treated ROS1 positive non small cell lung cancer, providing a fresh catalyst from its oncology pipeline. Despite the approval, GSK's share price has eased in recent weeks, with a 30-day return of negative 2.66% and a 90-day return of negative 5.67%, though the one-year total shareholder return stands at 42.21% and the five-year return at 65.00%. A widely followed narrative estimates GSK's fair value at £21.14 per share, compared to the last close of £19.06, suggesting the stock is about 9.9% undervalued. The valuation is underpinned by steady revenue expansion, firmer margins, and a rerating in the profit multiple, driven by strong volume growth in high-margin areas such as oncology, immunology, and HIV, as well as robust demand for vaccines and specialty medicines. However, the narrative also highlights risks including Zantac litigation cash outflows and future patent expiries that could undermine earnings assumptions.
Summit Therapeutics Reports $690.7 Million Cash Position and Ivanizumab Progress in Q2 2026
Summit Therapeutics reported a cash position of approximately $690.7 million at the end of the second quarter of 2026, up from the prior quarter. The company's lead investigational asset, Ivanizumab, has generated positive data in four Phase III clinical studies, securing two approvals in China and a pending Biologics License Application with the U.S. FDA. GAAP operating expenses rose to $220.5 million, driven by higher research and development costs. The HARMONY trial showed consistent overall survival benefit across regions, and Summit has initiated over 50 clinical trials for Ivanizumab across a range of solid tumors, while also establishing collaborations with GSK and Arcus Biosciences to explore novel combinations.
GSK's First Lung Cancer Drug Wins Early FDA Approval
British pharmaceutical giant GSK announced that its first lung cancer drug, Jiditro, has received marketing approval from the US Food and Drug Administration. The approval came ahead of the original review deadline, allowing GSK to enter the highly profitable lung cancer treatment market. Jiditro was acquired from the US biopharmaceutical company Newvalent, which GSK bought for 10.6 billion dollars about two months ago. It has been approved for patients with previously treated ROS1-positive non-small cell lung cancer. In early to mid-stage clinical trials, tumors shrank or disappeared in 44 percent of 117 patients, and among those who responded, 82 percent maintained their response at six months and 69 percent at twelve months. With this approval, GSK aims to accelerate the turnaround of its oncology business under new CEO Luke Miles and achieve its target of over 40 billion pounds in revenue by 2031.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Regulation
GSK.LSE · Regulation · Positive GSK's first lung cancer drug Jiditro received early FDA approval, enabling entry into the lung cancer market and supporting revenue targets.
NUVL · Demand · Positive GSK's drug Jiditro, acquired from Nuvalent, received FDA approval, validating Nuvalent's pipeline and potentially increasing its value.
Biotech IPOs Surge 55% as AI Listings Lose Momentum
Biotechnology and pharmaceutical IPOs have generated a weighted average return of 55% in the U.S. market this year, sharply outperforming the broader market's 4.4% weighted average loss, according to Bloomberg data through July 17. The strong performance is drawing more drug developers to go public, with at least six filing this month, led by Scribe Therapeutics, and the number of completed biotech IPOs in 2026 already surpassing last year's total while proceeds exceed $5 billion, roughly three times the prior year's amount. Parabilis Medicines raised $770.6 million in the largest biotech IPO on record, and Veradermics has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors. The sector's recovery is supported by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory environment, and renewed acquisition activity, including three deals valued at $10 billion or more announced in the past month involving AbbVie, GSK, and Vertex Pharmaceuticals. Investment bankers note that major fund groups are reallocating capital toward healthcare, though higher interest rates could pose a headwind.
GSK Drops Chronic Cough Drug Camlipixant After Mixed Trial Results
GSK has stopped developing its experimental chronic cough drug camlipixant after mixed late-stage trial results, sending shares down as much as 4.5 percent. The decision came after a high dose reduced cough frequency in one study but failed to meet the same goal in another trial involving a different patient population. The setback removes one of the company's limited late-stage clinical readouts expected this year and could add pressure to CEO Luke Miels' effort to lift annual sales to 40 billion pounds, or 53.8 billion dollars, by 2031. GSK had previously estimated camlipixant could generate more than 2.5 billion in annual sales, though some analysts projected only about 430 million by 2031. Analysts described the outcome as a credibility hit rather than a major financial setback, with some questioning the company's acquisition strategy after it spent 2 billion dollars to acquire the medicine.
Smart Inhalers Market to Reach $12.1 Billion by 2030
The global smart inhalers market is projected to grow from $5.2 billion in 2024 to $12.1 billion by 2030, a compound annual growth rate of 15.4%, according to a new report from BCC Research. The expansion is driven by poor medication adherence among asthma and COPD patients, with compliance rates often below 50%, leading to preventable hospitalizations and emergency visits. North America holds the largest market share, supported by digital health infrastructure and new CMS Remote Therapeutic Monitoring reimbursement codes. Key players include AstraZeneca, GSK plc, Novartis AG, Boehringer Ingelheim International GmbH, Adherium, and Amiko Digital Health Ltd.
UK
